Early signs and risk factors for the increased incidence of Epstein- Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

Transplantation

Volumn 64, Issue 10, 1997, Pages 1438-1442

  Sokal, Etienne Marc ^a   Antunes, Henedina ^a   Beguin, Claire ^a   Bodeus, Monique ^a   Wallemacq, Pierre ^a   De Ville De Goyet, Jean ^a   Reding, Raymond ^a   Janssen, Magda ^a   Buts, Jean Paul ^a   Otte, Jean Bernard ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; OKT 3; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PEDIATRIC SURGERY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK FACTOR; VIRUS INFECTION;

EID: 0030728955     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199711270-00011     Document Type: Article

References (13)

1. Sokal EM, Caragiozoglou T, Lamy M, Reding R, Otte JB. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993; 56: 1394.
2. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524.
3. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
4. European FK506 Multicenter Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
5. Belle SH, Beringer KC, Murphy JB, Detre KM. The Pitt-UNOS liver transplant registry. Clin Transpl 1992; 17.
6. Reding R, Wallemacq PE, Lamy M, et al. Conversion from cyclosporine to FK 506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994; 57: 93.
7. Reding R, Wallemacq P, Lamy M, et al. Conversion from cyclosporin to FK506 for salvage of immunocompromised pediatric liver allografts [Abstract]. Transplantation 1994; 57: 93.
8. Alberti D, Wallemacq P, Falchetti D, et al. Microemulsion formulation of cyclosporine in pediatric liver transplantation. Transplantation 1996; 61: 512.
9. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosupression with FK 506 vs cyclosporine. Transplantation Proceedings 1991; 23: 2977.
10. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996; 62: 370.
11. Morgan G, Superina RA. Lymphoproliferative disease after pediatric liver transplantation. J Pediatr Surg 1994; 29: 1192.
12. Hornef MW, Wagner H-J, Fricke L, Bein G, Kirchner H. Immunocytochemical detection of Epstein-Barr virus antigens in peripheral B lymphocytes after renal transplantation. Transplantation 1994; 59: 138.
13. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosupression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.